跳至主要内容
临床试验/EUCTR2007-005809-21-IT
EUCTR2007-005809-21-IT进行中(未招募)不适用

Treatment of Steroid refractory Graft versus Host Disease with monoclonal antibody B T 5/9 (anti-CD26) - ADN-GVHD vs BT 5/9

FONDAZIONE RICERCA TRAPIANTO DI MIDOLLO OSSEO0 个研究点开始时间: 2009年3月23日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • a)18 - 65 years
  • b)Signed informed consent must be obtained prior to conducting any study procedure
  • c)Acute GvHD II-IV grade
  • d)patients who underwent HSCT without distinction of donor type and/or of donor leukocyte infusions (DLI)
  • e)standard prophylaxis prior to transplantation
  • f)cyclosporine with methotrexate for GVHD prophylaxis after transplantation
  • g)Staging and grading of acute GVHD were according to the Glucksberg criteria
  • h)Acute GvHD II-IV grade not responding to 5 days of steroids
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • a)Life expectation < 10 day
  • b)Patients with Chronic GVHD
  • c)HIV+, HBsAg+ or HCV+
  • d)Multi-organ system failure
  • e)Subjects who developed a lymphoproliferative disorder after HSCT
  • f)pregnant and/or lactating

研究者

发起方
FONDAZIONE RICERCA TRAPIANTO DI MIDOLLO OSSEO

相似试验